OncoMed Pharmaceuticals Inc (OMED)

12.14
0.01 0.08
NASDAQ : Health Care
Prev Close 12.13
Open 12.04
Day Low/High 12.04 / 12.62
52 Wk Low/High 8.42 / 23.98
Volume 75.68K
Avg Volume 182.50K
Exchange NASDAQ
Shares Outstanding 30.30M
Market Cap 369.03M
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Purchase OncoMed Pharmaceuticals At $12.50, Earn 23% Annualized Using Options

Commit To Purchase OncoMed Pharmaceuticals At $12.50, Earn 23% Annualized Using Options

Investors eyeing a purchase of OncoMed Pharmaceuticals Inc. shares, but cautious about paying the going market price of $14.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.

7 Stocks Under $10 Making Big Breakout Moves

7 Stocks Under $10 Making Big Breakout Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering big breakouts.

OncoMed Provides Update On Tarextumab Phase 2 Programs

OncoMed Provides Update On Tarextumab Phase 2 Programs

Phase 2 PINNACLE Study in Small Cell Lung Cancer Continues Following DSMB and FDA Review

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of OncoMed Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of OncoMed Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc.

Noteworthy Monday Option Activity: OMED, ROCK, STAR

Noteworthy Monday Option Activity: OMED, ROCK, STAR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OncoMed Pharmaceuticals Inc. , where a total of 1,451 contracts have traded so far, representing approximately 145,100 underlying shares.

OncoMed (OMED) Stock Plummets on Pancreatic Cancer Drug Trial Results

OncoMed (OMED) Stock Plummets on Pancreatic Cancer Drug Trial Results

OncoMed (OMED) stock is dropping on heavy trading volume on Monday, after an independent study of its pancreatic cancer treatment reported negative results.

OncoMed Provides Update On Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial

OncoMed Provides Update On Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial

Management to Conduct Conference Call at 8:30 am ET

OncoMed Presents Updated Phase 1b Data For Demcizumab In First-Line Pancreatic Cancer At The Gastrointestinal Cancers Symposium

OncoMed Presents Updated Phase 1b Data For Demcizumab In First-Line Pancreatic Cancer At The Gastrointestinal Cancers Symposium

Demcizumab Plus Standard of Care Yields Median Overall Survival of 12.7 Months

Oversold Conditions For OncoMed Pharmaceuticals (OMED)

Oversold Conditions For OncoMed Pharmaceuticals (OMED)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Insider Trading Alert - MENT, TINY And OMED Traded By Insiders

Insider Trading Alert - MENT, TINY And OMED Traded By Insiders

Stocks with insider trader activity include MENT, TINY and OMED